No Data
No Data
Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress
Design Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
Design Therapeutics Analyst Ratings
RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)
Express News | Design Therapeutics Inc : Leerink Partners Raises Target Price to $5.00 From $4.00
Design Therapeutics GAAP EPS of -$0.21
No Data
Trytosaveabit : Ty! Yes it’s been on a decent uptrend on very low daily volume! Yesterday was a great climb again on less than 300K volume! I believe it’s recovering from the crash from FDA hold a few months ago?
Newbee4 OP Trytosaveabit : TY. GL today and everyday. Safe travels tomorrow
Trytosaveabit Newbee4 OP : Thank you pretty gal!